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Abstract
Background: Although behavioral risk factors are strongly associated with urinary tract infection (UTI) risk, the role of
genetics in acquiring this disease is poorly understood.
Methodology/Principal Findings: To test the hypothesis that polymorphisms in Toll-like receptor (TLR) pathway genes are
associated with susceptibility to UTIs, we conducted a population-based case-control study of women ages 18–49 years. We
examined DNA variants in 9 TLR pathway genes in 431 recurrent cystitis (rUTI) cases, 400 pyelonephritis cases, and 430
controls with no history of UTIs. In the Caucasian subgroup of 987 women, polymorphism TLR4_A896G was associated with
protection from rUTI, but not pyelonephritis, with an odds ratio (OR) of 0.54 and a 95% confidence interval (CI) of 0.31 to
0.96. Polymorphism TLR5_C1174T, which encodes a variant that abrogates flagellin-induced signaling, was associated with
an increased risk of rUTI (OR(95%CI): 1.81 (1.00–3.08)), but not pyelonephritis. Polymorphism TLR1_G1805T was associated
with protection from pyelonephritis (OR(95%CI): 0.53 (0.29–0.96)).
Conclusions: These results provide the first evidence of associations of TLR5 and TLR1 variants with altered risks of acquiring
rUTI and pyelonephritis, respectively. Although these data suggest that TLR polymorphisms are associated with adult
susceptibility to UTIs, the statistical significance was modest and will require further study including validation with
independent cohorts.
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Introduction
Acute uncomplicated urinary tract infections (UTIs) in young
women are exceedingly common and result in substantial
morbidity, time lost from work, and medical costs. Treatment
requires the frequent use of antibiotics which contributes to drug
resistance. Recurrent UTI (rUTI) is a common syndrome in
otherwise young healthy women. Previous studies suggest that
27% to 44% of women who experience an initial UTI develop
rUTI [1,2]. The vast majority of these women do not have
underlying functional or anatomic abnormalities of the urinary
tract. Although pyelonephritis is less common than cystitis, it is a
serious illness that can result in expensive hospitalization.
Behavioral factors, such as sexual intercourse and spermicide
use, are strongly associated with an increased risk of rUTI and
pyelonephritis [3,4,5]. However, many women with uncomplicat-
ed UTI do not have obvious behavioral, functional or anatomic
risk factors, suggesting that genetic risk factors may be present.
A series of studies over several decades indicates that host
genetic factors influence susceptibility to human infections [6,7,8].
More recent studies suggest an influence of genetics on
susceptibility to UTIs. In one family study, 15% of relatives of
pyelonephritis-prone children had a UTI history compared to 3%
of relatives of controls [9]. In adults, 65.5% of mothers, 60.7% of
daughters, and 48.6% of sisters of women with rUTI had a similar
history [10]. We previously found that adult women with rUTI or
pyelonephritis were more likely to have a mother with a UTI
history in comparison to controls [4,5]. Aside from associations of
non-secretor blood group antigens and P1 phenotype with RUTI
and/or pyelonephritis, we are not aware of any associations of
polymorphisms with UTIs in adults [11,12,13,14,15,16]. Genetic
studies in children have reported associations of polymorphisms in
CXCR1, TLR2, and TLR4 with UTI susceptibility [17,18,19,20].
In addition, reduced expression levels of CXCR1, CXCR2 and
TLR4 on neutrophils was associated with pyelonephritis, recurrent
cystitis and asymptomatic bacteriuria, respectively [18,21,22,23].
Mouse studies have also suggested a role for CXCR1 in UTI
susceptibility [21]. Although these studies suggest a possible role
for genetics in human UTI susceptibility, the genes involved
remain largely unknown.
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receptors that orchestrate the innate immune response and
recognize Pathogen-Associated Molecular Patterns (PAMPs) such
as bacterial flagellin (TLR5), lipopolysaccharide (LPS) (TLR4),
and bacterial lipopeptides (TLR1/2/6) [24,25,26]. During a UTI,
bacteria colonize the urethra and ascend to the bladder, where
they can persist at high levels and cause cystitis [27]. In addition,
pathogens may ascend to the kidney and cause serious
complications, including pyelonephritis and bacteremia [28].
The initial recognition of bacteria occurs at the epithelial cell
surface of the urogenital tract, a site of TLR expression in humans
[29]. E. coli, which causes 70–90% of all uncomplicated UTIs, is
recognized by several TLRs, including TLR1,2,4,5,6 and 11
[24,25,26]. Although previous studies in mice indicate that TLR4,
TLR5, and TLR11 regulate susceptibility to cystitis and
pyelonephritis, the role of TLRs in human UTI pathogenesis is
poorly understood [30,31,32,33].
We and others have characterized human TLR pathway
polymorphisms that are associated with altered gene function and
susceptibility to different infections [34,35,36,37,38,39,40,41,42,43].
Although two previous studies suggest that polymorphisms
TLR2_G2258A and TLR4_A896G are associated with susceptibility
to UTIs in children, the role of the other functionally significant TLR
polymorphisms in UTI pathogenesis is not currently known [19,20].
In addition, it is also not known whether any TLR variants are
associated with cystitis or pyelonephritis in adults. In this manuscript,
we summarize the results of a population-based case-control study
examining whether polymorphisms in TLR genes are associated with
susceptibility to cystitis and pyelonephritis in adultwomen ages 18–49
years.
Materials and Methods
Study Setting and Participants
The study protocols were approved by the Human Subjects
committees at Group Health Cooperative, the University of
Washington, and Western Institutional Review Board. The study
was conducted at Group Health Cooperative in Seattle,
Washington. We selected potential RUTI and pyelonephritis
cases from the health plan’s automated databases. Potential cystitis
subjects were identified through having received an International
Classification of Diseases (ICD-9) diagnosis code. Recurrent
cystitis (rUTI) case subjects were identified based on 3 diagnosed
UTI episodes within a 12-month time frame or 2 UTIs within 6
months (episodes were separated by at least 30 days). Culture
confirmation ($10
3 cfu/mL of a urinary pathogen) or UTI
guideline-related treatment was required for all UTI episodes in
the cluster. Potential pyelonephritis subjects were identified
through having received a pyelonephritis ICD-9 diagnosis code
and, if they received only outpatient treatment, a primary
diagnosis of pyelonephritis and an accompanying culture result
of $10
3 cfu/mL of a urinary pathogen or accompanying
antibiotic therapy appropriate for pyelonephritis. The remainder
of the women in the registries constituted the potential control
subjects who were randomly selected and frequency-matched by
case age group (age categories were 18–29, 30–39, 40–49 years).
Potential participants received a letter of invitation describing
the study and inviting their participation. In screening for
eligibility, exclusion criteria were kept to a minimum. Potential
participants were queried as to whether they could urinate on their
own and were ambulatory. In addition, potential control subjects
were asked about previous UTIs and were excluded if they
reported previous healthcare provider-diagnosed cystitis episodes.
If they reported a history of pyelonephritis or kidney infections,
they were enrolled in the pyelonephritis case group. Women who
were eligible and willing to take part in the study were scheduled
for a clinic visit where case histories of recurrent cystitis and/or
pyelonephritis were confirmed. The number of lifetime UTIs was
determined by self-reporting. For controls, we verified that they
had no history of UTIs. Ethnicity was determined by self-
identification. We identified 877 women as potential rUTI
subjects, 673 as potential pyelonephritis subjects, and 1,923 as
potential control women during recruitment. Of the potential
rUTI case participants, 431 (59%) of women identified as eligible
agreed to participate and completed their clinic appointments; 144
were identified as ineligible; 256 refused; and 46 could not be
reached. Among potential pyelonephritis case women, 400 (69%)
of women identified as eligible agreed and completed clinic
appointments; 89 were ineligible; 155 refused; and 29 could not be
reached. Of the identified potential control women, 430 (47%) of
identified eligible women agreed and made clinic visits; 999 were
ineligible, due in large part to having a history of cystitis; 440
refused; and 54 could not be reached.
Genomic techniques. Genomic DNA was purified from
peripheral blood by QIAamp DNA blood kit (Qiagen). For TLR2,
4, 5, MYD88 (Myeloid differentiation primary response gene 88),
TIRAP/MAL (TIR domain containing adapter/MYD88 adaptor-
like), TICAM1/TRIF (TIR-Domain-containing adaptor molecule
1/TIR domain-containing adaptor inducing interferon beta), and
TRAM (TRIF-related adaptor molecule), we sequenced the
coding region to look for polymorphisms. We attempted to
sequence 48 or 96 samples per gene depending on levels of
previous investigations. We obtained high quality sequence of the
entire coding region in 45 subjects for TLR2, 43 for TLR4, 46 for
TLR5, 86 for TIRAP, and 87 for TRIF. We amplified the coding
region by PCR, sequenced it with Big Dye Terminator v3.0 and
then analyzed it on an ABI PRISM 3730 capillary sequencer
(Applied Biosystems). Sequence was aligned and analyzed with the
programs PHRED/PHRAP and CONSED [44]. For genotyping
in the full cohort, we generated haplotype tagging SNPs from our
sequencing data as well as publicly available data from the Innate
Immunity Program in Genomic Applications (IIPGA, http://
innateimmunity.net/). For determining haplotype tagging SNPs,
we used a multilocus linkage disequilibrium measure based on
generalized mutual information,which is also known as relative
entropy or Kullback-Leibler distance [45]. Genotyping was
carried out with a MassARRAY
TM technique (Sequenom) as
previously described [46,47].
Statistical Analyses. We evaluated the associations of case-
control status (the outcome) and SNP genotypes under log-
additive, recessive, and dominant models. In the log-additive
model (also called an allelic trend test), common homozygous
genotypes (00) were assigned a value of 0, heterozygotes (01) a
value of 1, and minor homozygous genotypes (11) a value of 2.
Odds ratios and significance levels were then assessed using a
logistic regression model. For the dominant model analysis, we
combined genotypes 01 and 11 and compared to genotype 00. For
the recessive model, we compared genotypes 00 and 01 versus
genotype 11. We also evaluated the association of case-control
status with haplotypes of SNPs in constructed with an
Expectation/Maximization (EM) algorithm with the program
HPlus as previously described [48]. We analyzed the rUTI and
pyelonephritis cases separately and in combination. Two-sided
testing was used for all comparisons to evaluate statistical
significance, considering a P-value of #0.05 as significant. We
evaluated the associations of SNPs with UTI intensity using a
linear regression model for each case group and combined case
groups. The coefficient with respect to SNP represents increased/
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the strength of the association of SNP genotypes with UTI
intensity. To verify that our significant findings were not due to
population admixture, we also performed Caucasian subgroup
analyses. All analyses were performed using the software Hplus or
SAS [48]. Hardy-Weinberg equilibrium (HWE) testing was
performed for all SNP genotypes using Haploview. Except for
minor deviations, all SNP genotypes satisfied Hardy-Weinberg in
the Caucasian control group.
Results
TLR polymorphism discovery
We used a case-control study design to examine whether TLR
pathway gene polymorphisms were associated with susceptibility
to recurrent cystitis and/or pyelonephritis in adult women. Cases
and controls had a similar mean age and ethnic composition and
were generally healthy with minimal co-morbid conditions
(Table 1). We selected 9 genes for analysis, including TLRs 1, 2,
4, 5, 6 due to their central role in recognizing E. coli and other
UTI-associated pathogens. We also chose to examine the adaptor
molecules associated with these TLRs, including MYD88, TIRAP,
TRIF, and TRAM. In order to discover novel polymorphisms
associated with UTIs, we PCR-amplified and sequenced the
coding regions of 7 TLR pathway genes (TLR2, TLR4, TLR5,
MYD88, TIRAP, TRIF, and TRAM) in subjects with a high
frequency of cystitis or pyelonephritis episodes. We did not
discover any polymorphisms at .2% frequency in MYD88 or
TRAM, so these genes were not studied further. We discovered
previously reported polymorphisms in TLR2 (n=45 subjects),
TLR4 (n=43), TIRAP (n=86), and TRIF (n=87) in this study
population. In TLR5, among 46 case women, we found several
previously reported polymorphisms as well as two novel SNPs
(C541A (Q181K), ss136261639 in the NCBI dbSNP database
(http://www.ncbi.nlm.nih.gov/SNP/) in 4/46 and A2254G
(R752G), ss136261646 in 1/40). Together, the results for these 5
genes suggest that nearly all polymorphisms were previously
available in public databases for genotyping strategies.
For our primary analysis, we examined whether 7 well-
characterized TLR-pathway SNPs were associated with UTIs.
Previous studies suggest that these SNPs are associated with altered
TLR gene function and susceptibility to different infections. The
polymorphisms include TLR1_G1805T (amino acid (AA) change
S602I), TLR2_G2258A (AA R753Q), TLR4_A896G (AA D299G),
TLR4_C1196T (AA T399I), TLR5_C1174T (AA R392STOP),
TIRAP_C539T (AAS180L), and TIRAP_C558T (AA A186A)
[34,35,36,37,38,39,40,41,42,43]. Although TIRAP_C558T is a
synonymous SNP, we have previously shown that it is associated
with altered cytokine production in response to PAM2 stimulation
[36]. We compared allele and genotype frequencies between cases
andcontrols and foundassociationsbetween SNPsTLR5_C1174T,
TLR4_A896G, and TLR1_G1805T with UTI outcomes. Due to
the presence of population heterogeneity in the entire cohort, we
analyzed data in both the Caucasian subgroup as well as the entire
cohort (Tables 2–3 for Caucasian subgroup and Supplemental
Tables 1 and 2 for the entire cohort). The ethnic composition of the
case and control populations was similar with a predominance of a
Caucasian background in all groups (Caucasian frequency of 78.7%
in RUTI cases, 80.3% in pyelonephritis cases, and 73.7% in
controls, Table 1).
TLR1_G1805T is associated with protection from
pyelonephritis
We and others previously demonstrated that allele
TLR1_1805G is associated with deficient TLR1 signaling in
comparison to1805T[37,38,43]. We compared genotype frequen-
cies in case and control groups and found that TLR1_1805T was
associated with protection from UTIs in the combined rUTI and
pyelonephritis case group in Caucasians (Table 2 log-additive
model, OR(95%CI): 0.72 (0.53–0.97)). Functionally, we previously
Table 1. Characteristics of Cases and Controls.
Variable rUTI cases (N=431) Pyelo cases (N=400) Controls (N=430)
N( % )
* N( % )
* N( % )
*
Age at study enrollment, years (mean) 37.6 36.7 37.5
Ethnicity
American Indian/Alaska native 16 (3.7) 22 (5.5) 13 (3.0)
Asian 56 (13.0) 25 (6.3) 60 (14.0)
Black or African American 24 (5.6) 30 (7.5) 32 (7.4)
Native Hawaiian or Pacific Is. 7 (1.6) 9 (2.3) 10 (2.3)
Caucasian 339 (78.7) 321 (80.3) 317 (73.7)
Hispanic/Latino 29 (6.7) 40 (10.0) 26 (6.1)
Other 20 (4.6) 26 (6.5) 20 (4.7)
Health conditions (history of)
Kidney stones 13 (3.0) 46 (11.5) 5 (1.2)
Kidney failure/insufficiency 1 (0.2) 5 (1.3) 2 (0.5)
Diabetes (not during pregnancy) 8 (1.9) 23 (5.8) 10 (2.3)
Urinary Tract Procedure History
Bladder/kidney surgery 17 (3.9) 40 (10.0) 5 (1.2)
Cystoscopy 33 (7.8) 48 (12.1) 0
*Numbers and percentages in ethnicity subcategories can be greater than total number due to selection of more than one category for an individual.
doi:10.1371/journal.pone.0005990.t001
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1805TT mediates higher levels of signaling than 1805GG with a
mid-range level in 1805GT genotypes. In this study, we found that
genotype 1805TT was associated with protection from pyelone-
phritis in comparison to the 1805GT and GG genotypes (Table 2,
recessive model, OR(95%CI): 0.53 (0.29–0.96)). We next exam-
ined whether our results were influenced by effects of population
heterogeneity. We found similar associations in the entire cohort
with a protective effect of the 1805TT genotype seen when
comparing controls to pyelonephritis cases (Table S1,
OR(95%CI): 0.66 (0.47–0.93)).
TLR4_A896G is associated with protection from rUTI
Allele TLR4_896G has been associated with altered signaling in
response to LPS in some studies. In our study, allele 896G was
associated with protection from rUTI (Table 2, log-additive
model, OR(95%CI) 0.54 (0.31–0.96)), but not pyelonephritis in
the Caucasian subgroup. We also examined the genotype
frequencies using a dominant effect model and found that
genotypes 896AG/GG were associated with protection from
rUTI when compared to the 896GG genotype (Table 2,
OR(95%CI): 0.54 (0.32–0.96)). A similar association was seen in
the entire cohort (Table S1, log-additive model OR(95%CI) 0.60
(0.38–0.96)), These results suggest that TLR4_A896G is associated
with protection from rUTI, but not pyelonephritis.
TLR5_C1174T is associated with increased susceptibility
to rUTI
We next compared genotype frequencies in case and control
groups of polymorphism TLR5_C1174T, which encodes a stop
codon polymorphism that abrogates flagellin signaling. We
previously demonstrated that allele T acts in a dominant fashion
with respect to allele C [35]. The CT and TT gentoype
frequencies of control women were 0.068 and 0.008, respectively,
in comparison to women with rUTI who had frequencies of 0.122
and 0.003, respectively. These differences were statistically
significant when comparing genotype frequencies with a dominant
model (Table 2 dominant model, OR(95%CI): 1.81 (1.00–3.08)).
A similar trend was observed in the log-additive model that did not
reach statistical significance (OR(95%CI): 1.65 (0.89–3.05)). In
Table 2. Genotypic Analysis of Functional TLR SNPs in Caucasian Subgroup.
SNP group genotype Log-additive Model
Recessive Model 11 vs
00, 01
Dominant Model 01, 11
vs 00
00 01 11 OR (95% CI) P
a OR (95%CI) P OR (95%CI) P
TLR1 Control 139 (48.6) 114 (39.9) 33 (11.5)
G1805T rUTI 150 (49.5) 120 (39.6) 33 (10.9) 0.97 (0.76, 1.23) 0.781 0.94 (0.56, 1.56) 0.803 0.96 (0.70, 1.33) 0.827
Pyelo 134 (47.7) 129(45.9) 18 (6.4) 0.78 (0.55, 1.10) 0.158 0.53 (0.29, 0.96) 0.035 1.04 (0.75, 1.44) 0.828
Combined 284(48.63) 249 (42.6) 51 (8.7) 0.72 (0.53, 0.97) 0.033 0.73 (0.46, 1.17) 0.190 1.00 (0.75, 1.33) 0.994
TLR2 Control 297 (93.99) 19 (6.01) 0
G2258A rUTI 320 (94.96) 17 (5.04) 0 0.83 (0.42, 1.63) 0.588 0.83 (0.42, 1.63) 0.588
Pyelo 302 (94.38) 18 (5.63) 0 0.93 (0.48, 1.81) 0.835 0.93 (0.48, 1.81) 0.835
Combined 622 (94.67) 35 (5.33) 0 0.88 (0.50, 1.56) 0.662 0.88 (0.50, 1.56) 0.662
TLR4 Control 274 (87.5) 33 (10.5) 6(1.9)
A896G rUTI 310 (92.8) 23 (6.9) 1 (0.3) 0.54 (0.31, 0.96) 0.035 0.15 (0.02, 1.28) 0.084 0.54 (0.32, 0.93) 0.025
Pyelo 275 (47.7) 42(45.9) 1 (6.4) 0.94 (0.57, 1.57) 0.816 0.16 (0.02, 1.35) 0.092 1.10 (0.69, 1.75) 0.692
Combined 585 (89.7) 65 (10.0) 2 (0.3) 0.72 (0.46, 1.15) 0.169 0.16 (0.03, 0.79) 0.024 0.81 (0.53, 1.23) 0.311
TLR4 Control 277 (87.66) 35 (11.08) 4 (1.27)
C1196T rUTI 312 (92.31) 26 (7.69) 0 0.66 (0.39, 1.12) 0.126 0.59 (0.35, 0.998) 0.049
Pyelo 277 (86.56) 43 (13.44) 0 1.23 (0.76, 1.98) 0.397 1.10 (0.69, 1.75) 0.680
Combined 589 (89.51) 69 (10.49) 0 0.93 (0.60, 1.43) 0.731 0.83 (0.55, 1.26) 0.388
TLR5 Control 292 (92.7) 21 (6.8) 2(0.6)
C1174T rUTI 295 (87.5) 41 (12.2) 1 (0.3) 1.65 (0.89, 3.05) 0.110 0.47 (0.04, 5.16) 0.534 1.81 (1.00, 3.08) 0.030
Pyelo 293(91.6) 26 (8.1) 1 (0.3) 1.06 (0.57, 1.97) 0.848 0.49 (0.04, 5.44) 0.562 1.17 (0.17, 2.09) 0.596
Combined 588 (89.5) 67 (10.2) 2 (0.3) 1.37 (0.78, 2.41) 0.275 0.48 (0.07, 3.41) 0.461 1.49 (0.91, 2.44) 0.113
TIRAP Control 225 (71.66) 79 (25.16) 10 (3.18)
C539T rUTI 251 (74.26) 77 (22.78) 10 (2.96) 0.87 (0.61, 1.25) 0.464 0.93 (0.38, 2.26) 0.867 0.88 (0.62, 1.24) 0.454
Pyelo 237 (74.53) 75 (23.58) 6 (1.89) 0.57 (0.20, 1.59) 0.284 0.59 (0.21, 1.63) 0.304 0.86 (0.61, 1.23) 0.416
Combined 488 (74.39) 152 (23.17) 16 (2.44) 0.89 (0.65, 1.22) 0.455 0.76 (0.34, 1.69) 0.502 0.87 (0.64, 1.18) 0.367
TIRAP Control 192 (61.34) 107 (34.19) 14 (4.47)
C558T rUTI 181 (55.02) 131 (39.82) 17 (5.17) 1.30 (0.94, 1.80) 0.116 1.16 (0.56, 2.40) 0.683 1.30 (0.95, 1.78) 0.105
Pyelo 190 (59.94) 110 (34.70) 17 (5.36) 1.23 (0.59, 2.56) 0.587 1.21 (0.59, 2.50) 0.607 1.06 (0.77, 1.46) 0.718
Combined 371 (57.43) 241 (37.31) 34 (5.26) 1.17 (0.88, 1.55) 0.295 1.19 (0.63, 2.25) 0.599 1.18 (0.89, 1.55) 0.249
aP-value,0.05 is in bold.
doi:10.1371/journal.pone.0005990.t002
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frequencies in women with pyelonephritis versus controls. The
entire cohort showed a similar association in the genotype analysis
(Table S1 dominant model, OR(95%CI): 1.69 (1.06–2.70)). These
results indicated that TLR5-deficiency is associated with increased
susceptibility to rUTI, but not pyelonephritis. Together, these data
provide evidence that SNPs TLR1_G1805T, TLR4_A896G, and
TLR5_C1174T are associated with an altered risk of UTIs.
However, the magnitude of the effect and the statistical
significance were modest.
None of the other functional TLR SNPs were associated with
UTI susceptibility in allelic or genotypic analyses (Table 2). We
also generated haplotype tagging SNPs for TLRs 2, 4, 5, TIRAP,
and TRIF from our sequencing data as well as TLR1 and 6 from
public databases (Innate Immunity Programs for Genomic
Applications database (http://innateimmunity.net/)). We derived
46 haplotype tagging SNPs, including the 7 functional SNPs that
had been initially analyzed. We examined whether the genotype
and haplotype frequencies of these polymorphisms differed in the
pyelonephritis or rUTI case groups in comparison to the control
group with no history of UTIs (Table 3 and Table S2). In this
group of TLR pathway polymorphisms, there were occasional
SNPs with associations with UTI risk, but they were no
polymorphisms with known function, of a large magnitude, of
high statistical significance, or clustered within single genes
(Table 3 and Table S2, see SNPs TLR1_T130C,
TLR4_zA11547G, and TRIF_C1671T). We also examined
TLR1, TLR4, and TLR5 haplotypes to determine whether other
SNPs in these genes modified the association with UTI
susceptibility. We did not find any stronger associations within
haplotypes to suggest additive or synergistic associations when the
alleles were examined together (data not shown).
TLR Polymorphisms & UTI Disease Intensity
We next examined whether SNPs TLR1_G1805T,
TLR4_A896G, and TLR5_C1174T are associated with UTI
disease intensity (expressed as the number of lifetime UTIs divided
by age). Allele TLR5_1174T was associated with an increased
number of rUTI episodes in the allelic (coefficient 0.29, P=0.018)
and genotypic analysis (dominant comparison, coefficient 0.31,
P=0.018) (Table 4). Allele 896G was associated with a decreased
number of UTI episodes in the combined case group (coefficient -
0.34, P=0.011) and pyelonephritis group (coefficient -0.47,
P=0.033) (Table 4). Similar associations were found with the
genotypic analysis (dominant comparison, combined case group
coefficient -0.33 (P=0.020) and pyelonephritis coefficient -0.50
(P=0.027)). Together, these results suggest that SNPs
TLR5_C1174T and TLR4_A896G are associated with altered
UTI disease intensity as well as disease susceptibility.
Discussion
In these analyses, we examined whether polymorphisms from
the TLR pathway are associated with susceptibility to serious and
recurrent UTI. The major findings of our study were that SNP
TLR5_C1174T was associated with increased susceptibility to
RUTI, SNP TLR4_A896G was associated with protection from
RUTI, and SNP TLR1_G1805T was associated with protection
from pyelonephritis. There are several possible mechanisms by
which TLRs might affect the pathogenesis of cystitis and
pyelonephritis. If bladder and kidney epithelial cells have a
TLR-mediated signaling defect, then initial recognition of E. coli
would be impaired and activation of signaling pathways might be
delayed. In addition, neutrophils or monocytes that are recruited
to the bladder might have altered responses and result in greater
susceptibility to UTIs. Alternatively, or in addition, TLRs may
regulate dendritic cell maturation and influence the activation and
maintenance of T cell responses to E. coli antigens.
Previous studies have demonstrated that each of these 3
polymorphisms regulates signaling at the molecular and cellular
level. SNP TLR4_A896G has been associated with decreased in
vitro signaling in response to LPS in some studies as well as
decreased in vivo bronchial airway responsiveness. (reviewed in
[40]). Other studies did not find a difference in signaling and
suggested that any functional alteration may be dependent on the
assay conditions. We previously described that SNP
TLR5_C1174T, which encodes a stop codon polymorphism,
abolishes flagellin signalling, and is associated with increased
susceptibility to Legionnaires’ Disease [35]. More recently, we and
others discovered that SNP TLR1_T1805G is associated with
deficient TLR1 signaling as well as susceptibility to leprosy and
leprosy reversal reaction [37,38,41,43]. Cells from 1805TT
individuals secrete 5–10 fold greater amounts of IL-6 than
1805GG cells when stimulated with PAM3, a TLR1 ligand.
Intriguingly, Johnson et al also found that the TLR1 signaling
defect is due to a complete absence of TLR1 on the surface of
monocytes in GG individuals [38]. Recent studies have found
associations with tuberculosis and sepsis [43,49]. Greater than
80% of UTIs are caused by E. coli with other pathogens including
Staphylococcus saprophyticus, and Proteus, Enterobacter, Klebsiella, Pseudo-
monas, and Enterococcus species. Each of these pathogens are known
or predicted to contain cell wall lipopeptides, which are the
classical ligands for TLR1-TLR2 activation.
Although numerous studies have consistently documented
several behavioral risk factors for acquiring urinary tract
infections, accumulating evidence suggests that genetic factors
are also important. Aside from associations of non-secretor blood
group antigens and P1 phenotype with RUTI and/or pyelone-
phritis, we are not aware of any other associations of polymor-
phisms with UTIs in adults [11,12,13,14,15,16]. Several studies to
date have reported associations of polymorphisms with UTI
susceptibility in children. Two separate studies reported associa-
tions of CXCR1 variants with pyelonephritis [17,18]. Karoly et al
found an association of SNP TLR4 A896G with an increased risk
of UTI in Hungarian children (103 cases and 235 controls) and
Tabel et al found that TLR2 SNP G2258A (R753Q) was
associated with UTI risk in Turkey (124 cases and 116 controls)
[19,20]. In addition, reduced levels of TLR4 expression on
neutrophils was found in women with asymptomatic bacteriuria in
comparison to controls [22]. Our TLR4 findings showed an
opposite effect in comparison to the Karoly study. Possible
explanations for the lack of confirmation of the TLR2 and TLR4
findings in our study include differences in age (pediatric vs adult),
ethnicity, and polymorphism frequency (frequency of G2258A was
2% in our population in comparison to 5–13% in Turkey). It is
intriguing that two genetic UTI studies have identified associations
of TLRs involved in lipopeptide recognition (TLR2 and TLR1)
and independently suggest an important role for this pathway in
UTI pathogenesis.
Our study has several strengths and weaknesses. Potential
weaknesses include effects of population admixture and multiple
comparisons. To account for possible confounding effects from
population heterogeneity, we performed our analyses in the
Caucasian subgroup as well as the entire cohort. In addition, we
enrolled our control participants from the same defined population
as the cases, thus minimizing biases that might arise from a more
opportunistic source of controls. Despite these attempts to
minimize population admixture effects, we cannot exclude this
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5990possibility. For example, recent studies of the ancestry of European
Americans indicates population substructures that could be a
source of admixture [50]. This issue can be most convincingly
addressed by validation of these findings in an independent study.
A second possible limitation is the issue of multiple comparisons.
SNPs with well-characterized function do not generally have the
same requirement for adjustments for multiple comparisons due to
a well-founded a priori hypothesis of their potential association with
a cellular function. As a matter of hypothesis testing, we prioritized
seven well-characterized functional polymorphisms in our primary
analysis. From these seven tests, we identified three significant
associations and arguably no adjustments are necessary. As a
secondary analysis, we genotyped an additional 39 SNPs to
determine whether haplotypes containing the 7 functional SNPs
were associated with outcome. If a strict Bonferroni correction
were taken, none of them would survive adjustment for multiple
comparisons after multiplying the observed P values by seven or
46. However, a Bonferroni correction is arguably too stringent in
this context. Although haplotype tagging polymorphisms are
deliberately selected to have low levels of pairwise linkage
disequilibrium, we also included additional SNPs identified in
the sequencing of the coding region. The SNPs within each gene
had low levels of linkage disequilibrium and were thus not fully
independent tests. An alternative adjustment would be to use a
False Discovery Rate method which estimates the likelihood that
our findings are false. By this method, the chance of falsely
observing three significant tests out of seven is quite low at
approximately 11.6% (760.05/3). Regardless of which adjust-
ments are chosen for our data, convincing evidence of a genetic
effect ultimately requires multiple replication studies as well as
detailed analysis of functional effects of each polymorphism.
Our study also had numerous strengths. First, to our knowledge
this is the largest study to examine gene polymorphisms and UTI
susceptibility and is the only study to date to examine this
phenotype in adults. Second, to avoid a possible bias from age, we
frequency matched controls to cases by age group to insure that
there was similar exposure time for the development of UTIs.
Finally, we enrolled subjects in a well-characterized population
and verified diagnoses identified through automated indices with a
clinic visit to collect additional clinical history.
Our findings raise several mechanistic questions about the role of
different TLRs in UTI pathogenesis and how their effect differs for
cystitisandpyelonephritisrisk.Expression ofindividualTLRs varies
in different genitourinary tissues. We previously demonstrated in a
mouse model that TLR5 plays a crucial role in host defense to
uropathogenic E. coli by limiting bacterial replication in both the
bladder and kidney [30]. Other investigators have demonstrated
that TLR4-deficient C3H/HeJ mice exhibit a reduced inflamma-
tory response to E. coli and exhibit significantly higher bacterial
counts in the bladder and kidneys [31,51,52]. Although TLR4 is
expressed on urinary epithelium, there is conflicting evidence about
whether the epithelial cells respond to LPS [53,54,55,56,57]. We
found that the murine bladder was highly responsive to in vivo
injection of flagellin, but relatively unresponsive to highly purified
LPS [30]. These experiments suggest that TLR5 and TLR4
mediate distinct bladder innate immune responses with TLR5
regulating a relatively dominant role initially.
In summary, our results suggest that well-characterized
polymorphisms in TLRs 1, 4, and 5 are associated with altered
risks of UTI in adult women. Our work, along with others,
contributes to an increased understanding of the importance of
genetic variants that, along with behavioral risk factors, influence
UTI susceptibility.
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Table S2
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Table 4. Analysis of 3 Functional TLR SNPs with UTI Disease Intensity.
SNP group Log-additive Model Recessive Model
c Dominant Model
Coefficient (stdev)
a P
d coefficient (stdev)
b P coefficient (stdev)
b P
TLR1 RUTI 0.10 (0.06) 0.102 0.09 (0.10) 0.398 0.14 (0.09) 0.113
G1805T Pyelo 0.23 (0.11) 0.034 0.25 (0.19) 0.185 0.30 (0.16) 0.053
Combined 0.16 (0.06) 0.009 0.15 (0.10) 0.160 0.22 (0.09) 0.012
TLR4 RUTI 20.16 (0.16) 0.321 20.54 (0.61) 0.373 20.16 (0.16) 0.312
A896G Pyelo 20.47 (0.22) 0.033 22.51 (1.43) 0.080 20.50 (0.22) 0.027
Combined 20.34 (0.13) 0.011 21.23 (0.69) 0.070 20.33 (0.14) 0.020
TLR5 RUTI 0.29 (0.12) 0.018 0.39 (0.61) 0.521 0.31 (0.13) 0.018
C1174T Pyelo 20.09 (0.25) 0.715 23.03 (1.42) 0.034 0.00 (0.26) 0.995
Combined 0.12 (0.13) 0.361 20.78 (0.68) 0.247 0.16 (0.13) 0.235
aCoefficient represents increase/decrease (positive/negative) in number of lifetime UTIs divided by age for each variant allele.
bCoefficient represents the difference in number of lifetime UTIs divided by age between the comparison groups.
cRecessive model comparison is unreliable due to small numbers of minor allele homozygotes.
dP values#0.05 in bold.
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